Amarin is a pharmaceutical company built around a single product: VASCEPA (branded VAZKEPA in Europe), a prescription purified omega-3 EPA capsule approved for two uses — reducing severely elevated triglycerides, and reducing the risk of major cardiovascular events in high-risk patients already on statin therapy. The cardiovascular indication, supported by the REDUCE-IT trial showing a 25% relative risk reduction in major adverse cardiovascular events, is the more commercially significant. VASCEPA's core clinical pitch is that it addresses residual cardiovascular risk in statin-treated patients who still have elevated triglycerides. In the U.S., Amarin sells through drug wholesalers and competes by securing managed care formulary exclusives with PBMs and insurers, which steer patients toward the branded product over cheaper generics. This is critical because key U.S. patents were invalidated in 2020, and at least eight generic manufacturers have since entered the market. Outside the U.S., Amarin uses a fully partnered model — supplying finished product to regional partners and earning supply revenue, royalties, and milestone payments. In Europe, Recordati holds an exclusive license covering 59 countries, with IP protection running to 2039. Amarin does not manufacture VASCEPA itself, relying instead on contract manufacturers. Following a mid-2025 restructuring that eliminated most European commercial roles, Amarin is targeting roughly $70M in annualized operating expense savings and expects positive cash flow in 2026. Management has also engaged Barclays to evaluate strategic transactions.